Wu Long, Kensiski Allison, Gavzy Samuel J, Song Yang, Lwin Hnin Wai, France Michael, Kong Dejun, Li Lushen, Lakhan Ram, Saxena Vikas, Piao Wenji, Shirkey Marina W, Mas Valeria R, Lohmar Brendan, Shu Yan, Bromberg Jonathan S, Ma Bing
University of Maryland School of Medicine, Department of Surgery, Baltimore, MD, USA.
University of Maryland School of Medicine, Center for Vascular and Inflammatory Diseases, Baltimore, MD, USA.
bioRxiv. 2025 Jul 11:2025.01.02.631100. doi: 10.1101/2025.01.02.631100.
Lifelong immunosuppressive therapy is required to prevent allograft rejection in organ transplantation. Current immunosuppressants effectively suppress adaptive and innate immune responses, but their broad, antigen-non-specific effects often result in severe off-target complications. It remains a significant unmet medical need in transplant medicine.
In this study we investigated immunosuppressant effects of four major immunosuppressant classes, including tacrolimus, prednisone, mycophenolate mofetil (MMF), and fingolimod (FTY), on the gut microbiome, metabolic pathways, lymphoid architecture and lymphocyte trafficking after up to 30-day chronic exposure. Despite their distinct mechanisms of action and not designed to target the gut, all immunosuppressive drugs induced profound and time-dependent alterations in both intestine gene expression and gut microbiome composition. Progressive alterations from moderate early, drug-specific changes to a strikingly convergent microbial dysbiosis, marked by significant expansion of pathobionts of , occurred across all drug classes. Concurrently, all drugs uniformly induced significant suppression of mucosal immunity including B cell, immunoglobulin, and antigen recognition. Time-dependent changes in lymph node (LN) reorganization and cellular composition were also observed, marked by a progressive shift toward pro-inflammatory phenotypes in gut-draining mesenteric LNs and a gradual loss of tolerogenic architecture in peripheral LNs. Drug-specific metabolic alterations and distinct phases of intestinal transcriptional responses were also characterized. Notably, MMF and FTY demonstrated the most robust immunomodulatory properties, and were able to suppress alloantigen-induced inflammation through mediating regulatory T cell distribution and LN remodeling.
Together, these findings highlight the underappreciated complexity and temporal dynamics immunosuppressants effects, particularly their impact on the gut and compartmentalized regulation of alloimmune in lymphoid tissues. Understanding these relationships offers new opportunities for refining immunosuppressive strategies to reduce treatment-related off-target complications and improve long-term organ transplant outcomes.
器官移植中需要终身进行免疫抑制治疗以防止同种异体移植排斥反应。目前的免疫抑制剂能有效抑制适应性免疫和先天性免疫反应,但其广泛的、非抗原特异性作用常常导致严重的脱靶并发症。这仍是移植医学中一项重大的未满足医疗需求。
在本研究中,我们调查了四类主要免疫抑制剂,包括他克莫司、泼尼松、霉酚酸酯(MMF)和芬戈莫德(FTY),在长达30天的慢性暴露后对肠道微生物群、代谢途径、淋巴结构和淋巴细胞迁移的免疫抑制作用。尽管它们的作用机制不同且并非针对肠道设计,但所有免疫抑制药物均在肠道基因表达和肠道微生物群组成上诱导了深刻且随时间变化的改变。所有药物类别均出现了从早期适度的、药物特异性变化到显著趋同的微生物失调的渐进性改变,其特征为特定致病共生菌的显著扩增。同时,所有药物均一致地显著抑制黏膜免疫,包括B细胞、免疫球蛋白和抗原识别。还观察到淋巴结(LN)重组和细胞组成随时间的变化,其特征为肠道引流肠系膜淋巴结中逐渐向促炎表型转变,以及外周淋巴结中耐受性结构的逐渐丧失。还对药物特异性代谢改变和肠道转录反应的不同阶段进行了表征。值得注意的是,MMF和FTY表现出最强的免疫调节特性,并且能够通过介导调节性T细胞分布和淋巴结重塑来抑制同种异体抗原诱导的炎症。
总之,这些发现突出了免疫抑制剂作用未被充分认识的复杂性和时间动态性,特别是它们对肠道的影响以及对淋巴组织中同种异体免疫的分区调节。了解这些关系为优化免疫抑制策略提供了新机会,以减少与治疗相关的脱靶并发症并改善长期器官移植结果。